A clinical trial to evaluate elamipretide in patients with cardiomyopathy associated with Duchenne muscular dystrophy
Latest Information Update: 12 Aug 2021
At a glance
- Drugs Elamipretide (Primary)
- Indications Cardiomyopathies; Duchenne muscular dystrophy
- Focus Therapeutic Use
- Sponsors Stealth BioTherapeutics
- 05 Aug 2021 According to a Stealth BioTherapeutics media release,the company expectspre-IND meeting with the FDA to discuss protocol design for the trial during the second half of 2021.
- 19 Jun 2021 New trial record